Drugs / Salsalate
Salsalate
also known as
2-hydroxy-benzoic acid, 2-carboxyphenyl ester · DISALCID · Disalicyclic acid · disalicylate · NSC-49171 · Salicylic acid, bimolecular ester · Salicylsalicylic acid · Salsalato · +1 more
Small molecule targets IKBKB via inhibition
Trials 27
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06489249 | Aug 2024 → Jun 2026 overdue | — | University of Iowa | Recruiting | No outcome recorded |
| Phase 0 | NCT05069740 | Jan 2022 → Dec 2025 overdue | endometriosis | Penn State University | Recruiting | No outcome recorded |
| Phase 0 | NCT03482440 | Aug 2018 → Jul 2019 | preeclampsia | University of Iowa | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT03816488 | Dec 2023 → Jun 2024 | hyperglycemia, type 2 diabetes mellitus | McMaster University | Withdrawn | No outcome recorded |
| Phase 1 | NCT03277573 | Jul 2017 → Feb 2022 | Alzheimer disease | Adam Boxer | Completed | No outcome recorded |
| Phase 1 | NCT02422485 | Apr 2015 → Dec 2019 | progressive supranuclear palsy | Adam Boxer | Completed | No outcome recorded |
| Phase 1 | NCT01489319 | Feb 2012 → Jun 2015 | polycystic ovary syndrome | Indiana University | Terminated | No outcome recorded |
| Phase 1 | NCT02130804 | Jul 2011 → Oct 2013 | — | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT00837590 | Mar 2009 → Jun 2010 | obesity disorder, prediabetes syndrome | Indiana University | Terminated | No outcome recorded |
| Phase 1 | NCT00553995 | May 2008 → Dec 2013 | — | Boston University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05169060 | Jun 2023 → Feb 2027 expected | diabetic neuropathy | University of Iowa | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT00258128 | Jan 2000 → May 2008 | — | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04146038 | Oct 2020 → Oct 2021 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT03229408 | Dec 2018 → Feb 2024 | polycystic ovary syndrome | University of Illinois at Chicago | Completed | Met primary |
| Phase 2 | NCT01977417 | Nov 2012 → Apr 2021 | obesity disorder, prediabetes syndrome | Gary L. Pierce | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01775865 | Sep 2012 → Feb 2016 | arterial disorder, diastolic heart failure | Gary L. Pierce | Completed | No outcome recorded |
| Phase 2 | NCT01506726 | Mar 2012 → Oct 2014 | anemia | Harvey Jay Cohen | Terminated | Missed primary |
| Phase 2 | NCT01480297 | Nov 2011 → Apr 2012 | peripheral neuropathy, type 1 diabetes mellitus | University of Michigan | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT02936843 | Oct 2016 → May 2023 | peripheral neuropathy, type 1 diabetes mellitus | University of Michigan | Completed | No outcome recorded |
| Phase 2/3 | NCT00624923 | Sep 2008 → Jan 2015 | coronary artery disorder, obesity disorder | Joslin Diabetes Center | Completed | Missed primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT03222206 | Nov 2017 → Feb 2019 | NAFLD1, osteoarthritis | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01578486 | Jun 2011 → Jul 2015 | schizoaffective disorder, schizophrenia | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 4 | NCT00339833 | Mar 2003 → Jul 2008 | type 2 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT01514682 | Jun 2012 → Apr 2017 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01182727 | Aug 2010 → Nov 2011 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01201759 | Jul 2009 → May 2012 | spinal cord injury | University of Miami | Completed | No outcome recorded |
| — | NCT02406586 | Jul 2009 → Mar 2011 | diabetes mellitus, hypertensive disorder | Emory University | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT01670773 Comparator | Aug → Oct 2012 | — | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01046682 Comparator | Jan → Jul 2009 | HIV infectious disease | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00258115 Comparator | Dec 2003 → Oct 2007 | obesity disorder | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00799643 Comparator | Nov 2008 → Sep 2012 | type 2 diabetes mellitus | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00330733 Comparator | Jan 2007 → Aug 2010 | atherosclerosis, diabetes mellitus, noninsulin-dependent, 2 | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2/3 | NCT00392678 Comparator | Oct 2006 → Jul 2008 | type 2 diabetes mellitus | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00760019 Comparator | Aug 2005 → Oct 2009 | atherosclerosis | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT02007577 Comparator | Jul 2010 → Nov 2013 | prediabetes syndrome | Stanford University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-11-15 | Sunstar Americas | Results Third European JSDEI Seminar on Periodontitis and Diabetes Link sunstar.com ↗
A one-year study of over 280 patients found that the mean HbA1c level was 0.37 per cent lower in patients treated with salsalate compared with those in the placebo group within 48 weeks, he said. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-11-15 | Sunstar Americas | Third European JSDEI Seminar on Periodontitis and Diabetes Link sunstar.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | salsalate | “1. Salsalate, 4 gm/day. Salsalate is a potent inhibitor of nuclear transcription factor NF-κB activation.” NCT01514682 ↗ |
| Known as | 2-hydroxy-benzoic acid, 2-carboxyphenyl ester | “The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester.” NCT02422485 ↗ |
| Known as | DISALCID | “Salsalate 750 MG Oral Tablet [DISALCID]” NCT06489249 ↗ |
| Known as | Disalicyclic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | disalicylate | “high-dose salsalate (disalicylate) therapy” PMID 24390146 ↗ Jan 2014 |
| Known as | NSC-49171 | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | Salicylic acid, bimolecular ester | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | Salicylsalicylic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | Salsalato | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | Sasapyrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Action | Inhibit | “inhibiting the IKKB/NF-kB pathway with salsalate is a feasible approach” NCT00330733 ↗ |
| Modality | Small molecule | “salsalate, a salicylate that reduces basal and inflammation-induced lipolysis” PMID 39888728 ↗ Mar 2025 |
| Route | Oral | “Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided” NCT00392678 ↗ |
| Target | IKBKB | “inhibition of the inhibitor of the κB kinase (IKKβ)/NF-κB pathway” NCT02936843 ↗ |